189 related articles for article (PubMed ID: 23913364)
1. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Ramirez S; Li YP; Jensen SB; Pedersen J; Gottwein JM; Bukh J
Hepatology; 2014 Feb; 59(2):395-407. PubMed ID: 23913364
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
3. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.
Li YP; Ramirez S; Mikkelsen L; Bukh J
J Virol; 2015 Jan; 89(1):811-23. PubMed ID: 25355880
[TBL] [Abstract][Full Text] [Related]
4. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
Gottwein JM; Scheel TK; Jensen TB; Ghanem L; Bukh J
Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
[TBL] [Abstract][Full Text] [Related]
5. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
Pham LV; Ramirez S; Carlsen THR; Li YP; Gottwein JM; Bukh J
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
[TBL] [Abstract][Full Text] [Related]
6. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.
Li YP; Ramirez S; Jensen SB; Purcell RH; Gottwein JM; Bukh J
Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19757-62. PubMed ID: 23151512
[TBL] [Abstract][Full Text] [Related]
7. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.
Li YP; Ramirez S; Gottwein JM; Scheel TK; Mikkelsen L; Purcell RH; Bukh J
Proc Natl Acad Sci U S A; 2012 May; 109(18):E1101-10. PubMed ID: 22467829
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
[TBL] [Abstract][Full Text] [Related]
9. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.
Pedersen J; Carlsen TH; Prentoe J; Ramirez S; Jensen TB; Forns X; Alter H; Foung SK; Law M; Gottwein J; Weis N; Bukh J
Hepatology; 2013 Nov; 58(5):1587-97. PubMed ID: 23729237
[TBL] [Abstract][Full Text] [Related]
10. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
[TBL] [Abstract][Full Text] [Related]
11. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
[TBL] [Abstract][Full Text] [Related]
12. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
[TBL] [Abstract][Full Text] [Related]
13. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
14. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
[TBL] [Abstract][Full Text] [Related]
15. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells.
Li J; Zhou Q; Rong L; Rong D; Yang Y; Hao J; Zhang Z; Ma L; Rao G; Zhou Y; Xiao F; Li C; Wang H; Li YP
Antiviral Res; 2021 Sep; 193():105136. PubMed ID: 34252495
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
[TBL] [Abstract][Full Text] [Related]
17. Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.
Mathiesen CK; Prentoe J; Meredith LW; Jensen TB; Krarup H; McKeating JA; Gottwein JM; Bukh J
J Virol; 2015 Aug; 89(15):7758-75. PubMed ID: 25995244
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.
Gottwein JM; Scheel TK; Jensen TB; Lademann JB; Prentoe JC; Knudsen ML; Hoegh AM; Bukh J
Hepatology; 2009 Feb; 49(2):364-77. PubMed ID: 19148942
[TBL] [Abstract][Full Text] [Related]
19. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies.
Humes D; Ramirez S; Jensen TB; Li YP; Gottwein JM; Bukh J
Virology; 2018 Sep; 522():177-192. PubMed ID: 30032031
[TBL] [Abstract][Full Text] [Related]
20. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
Ramirez S; Bukh J
Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
